Clinical Trials Related to Follicular Lymphoma

Related studies linked through entity extraction aliases.

A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Status: TERMINATED
Phase: PHASE1/PHASE2

1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation

Status: COMPLETED
Phase: PHASE2

High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant

Status: COMPLETED
Phase: PHASE2

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Status: TERMINATED
Phase: PHASE1

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy

Status: COMPLETED
Phase: PHASE2

A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Status: COMPLETED
Phase: PHASE2

A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma

Status: COMPLETED
Phase: PHASE3

Treatment of Follicular Lymphoma With High Dose Therapy and Stem Cell Support Followed by Rituximab and Alpha Interferon

Status: COMPLETED
Phase: PHASE2

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Status: TERMINATED
Phase: PHASE1/PHASE2

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

Status: COMPLETED
Phase: PHASE1

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Status: COMPLETED
Phase: PHASE1

Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

Status: TERMINATED
Phase: PHASE2

Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Status: UNKNOWN
Phase: PHASE3

CD180 Overexpression in Follicular Lymphoma

Status: COMPLETED
Phase: N/A

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Status: TERMINATED
Phase: EARLY_PHASE1

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

Status: COMPLETED
Phase: PHASE3

PCAR-119 Bridge Immunotherapy Prior to Stem Cell Transplant in Treating Patients With CD19 Positive Leukemia and Lymphoma

Status: UNKNOWN
Phase: PHASE1/PHASE2

Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Status: COMPLETED
Phase: PHASE1

Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

Status: TERMINATED
Phase: PHASE2